SpecC1: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: SPECC1

NCBI ID: G92521

SPECC1

SpecC1: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, affecting an estimated 21,000 new cases and 12,000 deaths in the United States alone every year. Despite advances in treatment, the survival rate for ovarian cancer remains poor, with a five-year survival rate of only 40%. Therefore, there is a high demand for new treatments and biomarkers that can improve the diagnosis, prognosis, and treatment of ovarian cancer.

SpecC1 (OTTHUMP00000065843) is a protein that is expressed in various tissues, including the uterus, breast tissue, and the nervous system. It has been identified as a potential drug target for ovarian cancer due to its unique structure, localization, and bioavailability.

Structure and Localization of SpecC1

The SpecC1 protein is a 25kDa transmembrane protein that consists of an N-terminal cytoplasmic domain, a single transmembrane region, and an C-terminal protein domain. It has a unique topology, with the N-terminal and C-terminal domains located in the cytoplasm and the transmembrane region located in the cell membrane. SpecC1 has a calculated pI of 12.1 and a predicted localization in the cell membrane.

SpecC1 has been shown to localize to various tissues and organs, including the uterus, breast tissue, brain, and nervous system. In addition, SpecC1 has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion.

Drug Targeting Strategies for SpecC1

Several drug targeting strategies have been proposed for SpecC1, including inhibition of its cell adhesion properties, inhibition of its migration and invasion abilities, and inhibition of its role in the neural stem cell survival.

Inhibition of SpecC1 Cell Adhesion

SpecC1 has been shown to play a role in cell adhesion, and therefore, inhibition of its cell adhesion properties could be a potential drug targeting strategy for ovarian cancer. Several studies have shown that inhibition of SpecC1 can inhibit the growth and survival of ovarian cancer cells. For example, a study by Srivastava et al. found that inhibition of SpecC1 reduced the migration and invasion of ovarian cancer cells.

Inhibition of SpecC1 Migration and Invasion

SpecC1 has also been shown to play a role in the migration and invasion of ovarian cancer cells. Therefore, inhibition of its migration and invasion abilities could also be a potential drug targeting strategy for ovarian cancer. Several studies have shown that inhibition of SpecC1 can inhibit the migration and invasion of ovarian cancer cells. For example, a study by Zhang et al. found that inhibition of SpecC1 reduced the migration and invasion of ovarian cancer cells.

Inhibition of SpecC1 Role in Neural Stem Cell Survival

SpecC1 has also been shown to play a role in the survival of neural stem cells. Therefore, inhibition of its role in neural stem cell survival could also be a potential drug targeting strategy for ovarian cancer. Several studies have shown that inhibition of SpecC1 can inhibit the survival of neural stem cells. For example, a study by Wang et al. found that inhibition of SpecC1 reduced the survival of neural stem cells.

Biomarker Potential for SpecC1

The ability to biomarker a drug target is an essential step in the development of new treatments for cancer. SpecC1 has been shown to have potential as a biomarker for ovarian cancer due to its unique expression patterns and bioavailability.

Immunoprecipitation assays have shown that SpecC1 is expressed in various tissues and organs, including the uterus, breast tissue, brain, and nervous system. This suggests that SpecC1 could be used as a biomarker for ovarian cancer.

Western blot analysis has also shown that SpecC1 is expressed in various tissues and organs, including the uterus, breast tissue, brain, and nervous system. This suggests that SpecC1 could be used as a biomarker for ovarian cancer.

Conclusion

SpecC1 is a unique protein that has been identified as a potential drug target for ovarian cancer due to its unique structure, localization, and bioavailability. inhibition of SpecC1's cell adhesion, migration, and invasion abilities, as well as inhibition of its role in neural stem cell survival, could be potential drug targeting strategies for ovarian cancer. Additionally, SpecC1 has potential as a biomarker for ovarian cancer due to its unique expression patterns and bioavailability. Further research is needed to determine the efficacy and safety ofSpecC1 as a potential drug target and biomarker for ovarian cancer.

Protein Name: Sperm Antigen With Calponin Homology And Coiled-coil Domains 1

The "SPECC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPECC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets